Product Images Rizatriptan Benzoate
View Photos of Packaging, Labels & Appearance
- Label - lbl713351819
- Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1
- Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2
- Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3
- Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6‡‡ - rizatriptan fig4
- Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5
- Chemical Structure - rizatriptan str
Product Label Images
The following 7 images provide visual information about the product associated with Rizatriptan Benzoate NDC 71335-1819 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl713351819
This text provides information about a medication called Rizatriptan Benzoate 10mg, in a white round F25 tablet form, and it is recommended to store it at room temperature. The medication is a generic equivalent of Maxalt. The packaging is a blister pack containing 10 tablets. The manufacturer is Aurobindo Pharma Limited. Additionally, it warns to keep all drugs out of the reach of children. The expiration date is specified as "EXP MM/YY". The NDC number is 7133518191 08256101523487.*
Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1
This description provides an estimate of the probability of achieving an initial headache response within two hours in pooled studies 1, 2, 3, and 4. The figure shows the Kaplan-Meier plot illustrating the likelihood over time of attaining a headache response (no or mild pain) after receiving treatment with rizatriptan benzoate or placebo. The data is based on four placebo-controlled outpatient trials, and patients who took additional medication or did not experience headache relief before 2 hours were censored at that time.*
Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2
This text provides an estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other migraine medication over the 24 hours following the initial dose in pooled Studies 1, 2, 3, and 4. The data shown is from 4 placebo-controlled outpatient clinical trials, with patients not using additional treatments censored at 24 hours. The plot includes patients with and without headache response at 2 hours after the initial dose, and it mentions that remedication was not allowed within 2 hours post-dose.*
Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3
This text provides information about the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets within 2 hours in Pooled Studies 5 and 6. It includes details about the Kaplan-Meier plot of the probability over time of obtaining headache response following treatment with Rizatriptan Benzoate tablets or placebo. Data is based on two placebo-controlled outpatient trials (Studies 5 and 6) showing evidence of efficacy.*
Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6‡‡ - rizatriptan fig4
Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6. This graph shows the percentage of patients opting for a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or an alternative migraine medication within the 24 hours following the initial dose across different time points. The data is based on clinical trials and includes patients with varying responses to the initial dose.*
Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5
This is a chart showing the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The chart compares the effectiveness of Rizatriptan Benzoate OD Tablets (medication) against a placebo. The data presented is in the form of a line chart with percentage values on the y-axis and hours post Stage 2 dose on the x-axis.*
Chemical Structure - rizatriptan str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
